Table 2.
Chemotherapy regimen | Patients | |
---|---|---|
No. | % | |
5FU/folinic acid alone | 2 | 5 |
Additional oxaliplatin | 17 | 40 |
Additional oxaliplatin + cetuximab | 4 | 9 |
Additional oxaliplatin + bevacizumab | 1 | 2 |
Additional irinotecan | 3 | 7 |
Additional irinotecan + cetuximab | 3 | 7 |
Additional irinotecan + bevacizumab | 6 | 14 |
Additional oxaliplatin + sequential irinotecana | 3 | 7 |
Additional oxaliplatin + sequential irinotecana + cetuximab | 2 | 5 |
Additional oxaliplatin + sequential irinotecana + bevacizumab | 2 | 5 |
5FU 5-fluorouracil
aEither oxaliplatin followed by irinotecan or vice versa